Empowering the Immune System to Prevent and Treat Disease
VBI’s pipeline is comprised of vaccine and immunotherapeutic programs developed by virus-like particle technologies to target two distinct, but often related, disease areas – infectious disease and oncology.
We prioritize disease targets that are challenging, underserved, and where the human immune system, when powered and stimulated appropriately, can be a formidable opponent.
Our pipeline is unified in the mission to achieve better health for all.
Approved for use in the U.S. for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older
Approved for use in Israel under the brand name Sci-B-Vac®, for active immunization against hepatitis B virus (HBV) infection
Regulatory review for approval ongoing in Europe and Canada
Phase 1 (Complete)
VBI-1501 is a prophylactic eVLP vaccine candidate expressing a modified form of the gB antigen, gB-G.
Clinical data suggest that the modified gB-G antigen elicits both fibroblast and epithelial cell neutralization, with a qualitatively enhanced neutralizing response.
Phase 1/2 (ongoing)
VBI-2902 is a monovalent eVLP vaccine candidate expressing a modified, optimized, pre-fusion form of the SARS-CoV-2 (COVID-19) spike antigen.
The ongoing Phase 1/2 study is supported by funding from the Strategic Innovation Fund of the Government of Canada.
VBI-2905 is a monovalent eVLP candidate expressing the pre-fusion form of the spike protein from the Beta (B.1.351) variant, a strain first identified in South Africa.
This program is supported by funding from CEPI.
VBI-2901 is a multivalent pan-coronavirus vaccine candidate expressing a modified, optimized, pre-fusion form of the SARS-CoV-2 (COVID-19) spike antigen, as well as the SARS-CoV (SARS) and MERS-CoV (MERS) spike antigens on the surface of the eVLP particles.
This vaccine candidate is supported by funding from the Strategic Innovation Fund of the Government of Canada.
A suite of additional multivalent coronavirus vaccine candidates designed to evaluate the potential breadth of VBI’s eVLP technology.
Preclinical development of these vaccine candidates are supported by funding from CEPI.
VBI-2501 is a bivalent eVLP vaccine candidate consisting of a modified E glycoprotein (found on the surface of the Zika virus) and NS1 glycoprotein (secreted during Zika viral replication).
Preclinical data suggest that the modified E glycoprotein enhances neutralizing responses, and the NS1 T cell response enhances antibody response and protection.
Phase 2 (ongoing)
VBI-2601 is an immunotherapeutic candidate that builds on the 3-antigen conformation of VBI’s prophylactic HBV program, but has been reformulated to enhance B and T cell responses.
VBI-2601 is being developed in collaboration with Brii Biosciences as part of a potential functional cure for chronic HBV infection.
Phase 1/2a (ongoing)
VBI-1901 is a bivalent eVLP cancer vaccine immunotherapeutic candidate that uses CMV as a foreign viral antigen approach to cancer treatment by expressing two highly-immunogenic CMV antigens – gB and pp65.
Scientific literature suggests that CMV infection is prevalent in multiple solid tumors, including GBM. VBI-1901 was co-administered with two adjuvants in the Phase 2a portion of the ongoing study: GM-CSF and GlaxoSmithKline’s AS01 adjuvant system.
Browse our library of publications to read more about our science and pipeline candidates.